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CHAPTER 3 
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Deputy Chairwoman, Menschen fur Tierrechte-Bundesverband der 
Tierversuchsgegner e.V. (People for Animal Rights Germany-Federal 
Association against Vivisection) 
baumgartL@tierrechte.de 
Christiane Hohensee 
Scientific Advisor, Menschen fur Tierrechte-Bundesverband der 
Tierversuchsgegner e.V. (People for Animal Rights Germany-Federal 
Association against Vivisection) 
hohensee@tierrechte.de 
Introduction 
Article 23 of European Union (Eu) Directive 86/609/EEC required that Mem­
ber States promote the development and validation of alternative technologies 
and stated that the European Commission ( E c) "shall report before the end of 
1987 on the possibility of modifying tests and guidelines" (European Parliament, 
1986, Article 23 ). This Directive was replaced by Directive 2010 / 63/E U on the pro­
tection of animals used for scientific purposes, which now requires that Member 
States develop and validate alternative approaches much more precisely and 
specifies that the ultimate objective is the "full replacement of procedures on live 
animals for scientific and educational purposes, as soon as it is scientifically pos­
sible to do so" (European Parliament, 2010, Recital 10 ). However, having followed 
theinitiativesofMemberStatesformorethan3oyears, we see that developments 
to replace animal experiments occur more by accident than by design. Direc­
tive 2010/63/EU has not changed this either. This chapter explores the reasons 
why the development and approval of animal-free methods are not advancing 
more quickly, and why the numbers of animals used is not declining despite the 
development of new methods. Undoubtedly, there are complex, multifactorial 
reasons behind this. Our analysis leads us to the heart of the matter. There is no 
master plan and there are no responsible project managers who effectively pur­
sue the objectives of Directive 2010/63/EU at a national or EU level. 
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In 2015, we started collating individual measures in order to tackle the prob­
lems we encounter in our day-to-day work as an animal rights organization, 
defining five categories ( or pillars). We were encouraged to pursue our ideas 
by developments in the United States through concepts, such as Toxicology in 
the 21st Century-A Vision and a Strategy ( Tox21) (Krewski et al., 2010 ), as well 
as by the EU ban on the marketing of cosmetics tested on animals, which came 
into force in 2013. During this time, the Netherlands National Committee for 
the protection of animals used for scientific purposes (NCad) presented its 
plan, Transition to Non-Animal Research, referred to here as the NCad report 
(NCad, 2016a), becoming the first EU member state to present a road map for 
phasing out animal procedures and stimulating innovation without laboratory 
animals. Unfortunately, no EU Member State, so far, has publicly spoken out in 
favor of the Dutch initiative. On the contrary, its timeline has been criticized as 
being unrealistic, risking the safety of medical treatment, and hampering basic 
research. Only the government of the Brussels-Capital Region has put forward 
a plan to phase out animal experiments along the lines of the NCad report. 
Member States should show more support for such initiatives, which aspire to 
achieve the goal of full replacement stated in Directive 2010/63/EU. At the EU 
level, unfortunately, there is neither an overall strategy for phasing out the use 
of animals for scientific purposes nor for monitoring the implementation of 
the paradigm shift. It is important that changes take place, but how they take 
place is subject to debate. 
Writing from the point of view of a German animal rights organization, the 
main focus of this chapter is Germany. Although Germany claims to be espe­
cially committed to developing animal-free methods, it ranks among the high­
est in terms of animal experiments in the EU, together with France and the 
United Kingdom. 
1 Part 1: How Seriously Do Member States Take the Tasks and 
Obligations Stated in Directive 2010/63/EU? 
A master plan to end animal experiments requires suitable resources for effec­
tively reducing animal experiments and increasing market-ready animal-free 
methods. In the following we discuss steps towards that final goal. 
On 1 December 2016, the Netherlands became the first EU Member State 
to present a road map for "phasing out animal procedures and the promo­
tion of innovation without laboratory animals" (NCad, 2016a, p. 3). They are 
convinced that some uses of animals-currently required by law for safety 
testing of chemicals, food additives, pesticides, and (veterinary) medicines as 
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well as the commercial launch of biological products ( e.g., vaccines )-can be 
phased out by 2025, while maintaining existing safety levels. However, their 
road map recommends that regulatory pre-clinical tests for the registration 
of new biological substances/products not be phased out by 2025 because 
there is a lack of replacement methods. Similarly, animal experiments in 
the field of "curiosity-driven" (NCad, 2016a, p. 38) basic research is not to be 
terminated by 2025 because there is a basic right to freedom of research; 
and, as no one knows the subject of research in advance, animal experi­
ments cannot be easily replaced with new animal-free methods. Therefore, 
it has been necessary to implement 10-year plans for each individual area 
of research. In the case of animal experiments in applied and translational 
research (implementation of preclinical research in clinical development), 
which are also not to be phased out by 2025, the development of replace­
ment methods is to be accelerated. The aim is to reduce significantly the use 
of laboratory animals for education and training. The planning encompasses 
transition objectives, transition strategy, and management of the transition. 
There is every indication that the NCad report, commissioned by the former 
Minister for Agriculture, Martijn van Dam, has laid out solid project plan­
ning with the goal of effecting system change from animal use to animal-free 
procedures. 
This type of planning should have been initiated at an EU-wide level in 
2013 when Directive 2010/63/EU came into effect, requiring the phasing out 
of animal procedures and the acceleration of innovation without laborato­
ry animals. While no Member State has publicly spoken out in favor of the 
Dutch initiative, the German research association, Deutsche Forschungsge­
meinschaft (DFG) and the Allianz der Wissenschaftsorganisationen (Alli­
ance of Science and Research Organizations) issued a critical assessment of 
the plan, calling its timeline unrealistic and claiming it would endanger the 
safety of medical treatment and hamper basic research (BfR, 2017a). Accord­
ing to our organization (People for Animal Rights Germany-Federal Asso­
ciation against Vivisection), a good master plan has the following attributes: 
it includes all stakeholders, including the scientific community, industry, and 
animal rights/welfare organizations; it has robust monitoring to assess the 
paradigm shift towards animal-free science; and it has an active commitment 
of all stakeholders to implement the plan. The master plan for an end to ani­
mal experiments requires suitable resources that purposefully pursue this end 
by reducing animal experiments and increasing market-ready animal-free 
methods. 
The master plan's foundation rests on five pillars: 
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Here we refer to animal-free research in the field of applied and basic research. 
This research field includes methods that can replace animal testing in regu­
latory animal tests (in a narrow sense). The budget for animal-free research 
methods should be drastically increased, with the EU and its Member States 
implementing their own funding programs for replacement methods. Ger­
many, for example, is not a suitable role model: at present, "system-changing" 
replacement methods compete with "system-maintaining" refinement 
and reduction methods, because the three options are funded by the same 
programs. 
The EU needs to increase the budget for funding animal-free research. In the 
current funding period, only one program that is dedicated to replacement, 
EU-ToxRisk, is funded. This European collaborative project is funded by 
the EU Framework Program for Research and Innovation, Horizon 2020. The 
project started on January 11 2016 and will last for six years. It currently has 
only €30 million at its disposal (EU-ToxRisk, 2016), with 39 participating 
groups. By comparison, during the last funding period, the EU Seventh Frame­
work Program provided the project cluster, SEURAT-I, with €50 million in 
funding for work towards the replacement of in vivo systemic dose-toxicity 
testing (which ran until December 2016)-much more than the current 
funding. 
Special funding programs are essential for creating ready-for-series tech­
nologies, i.e., mass production in large amounts with a lower product prize; 
for example, the characteristics and viability of current cell systems must be 
improved to recreate the functions of the natural organ as accurately as pos­
sible; current organoid biotechnology needs to replicate the behavior of organs 
more closely; and the functions of the capillary system and immune system 
still need to be modeled. 
National and European budgets, especially for validation studies, are 
also necessary and the Eu Reference Laboratory for Alternatives to Animal 
Testing-European Centre for the Validation of Alternative Methods (EURL 
ECVAM) (EURL ECVAM, 2017a) should be provided with adequate resources. 
This demands a great deal of work. Validation and qualification of the new in 
vitro systems have been discussed in several workshops across the us. These 
workshops were hosted by the Anlerican Institute for Medical and Biologi­
cal Engineering (AIMBE) and the National Institutes of Health (NIH) at the 
NIH campus in Bethesda, Maryland. Representatives of the EURL ECVAM 
and of some European start-ups also took part. The participants determined 
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the need for a broader definition of validation for the integration of new 
platform technologies into preclinical safety evaluation. The new in vitro 
systems, such as the chip technologies ( cell and tissue platforms, microelec­
trode systems with connected measuring devices), biomarkers, and the qual­
ity of cell and tissue types derived from human stem cells were also seen as 
needing evaluation in terms of safety for preclinical applications and ef­
ficacy. The pharmaceutical industry, which is the primary customer of the 
new multi-organ on a chip systems, should also be more involved (AIMBE, 
2013). 
The EU Member States need to support the concept of To.x21, developed in 
the us (Krewski et al., 2010 ). The concept's goal is to provide a new basis for risk 
and safety assessments of substances and products ( i.e., regulatory toxicology), 
using new techniques that are human-specific; and to promote the use of ani­
mal tests only in exceptional cases ( see also the Integrated Approaches to Test­
ing and Assessment adopted by the Organization for Economic Cooperation 
and Development, OECD, 2017). The OECD now includes 35 countries around 
the world, across North and South America, Europe, and Asia. 
A research focus is also needed on the implementation of cell culture media 
ready for practical application and for which no animals suffer, i.e., without the 
use of fetal bovine serum ( see Redmond, 2018, in this Volume). Researchers in 
the us have been able to work with serum-free media in a defined system since 
1995 (Schaffner et al., 1995). 
1.2 Pillar 2: Animal-free Methods in Teaching and Scientifi-c Research 
Have to Be Expanded 
The goal of Pillar 2 is to establish academic chairs-with corresponding per­
sonnel and financial resources for research and teaching and regular profes­
sorships-for animal-free research methods, courses of study in the life sci­
ences that do not use animals, a broad range of papers not based on the use of 
animals, and an increased number of theses and higher qualifications, with a 
focus on animal-free methods. 
In Germany, for example, individual chairs in some federal states or Bundes­
liinder (Baden-Wiirttemberg, Berlin, Hesse, and North Rhine-Westphalia) have 
been established to develop methods to replace animal use. Researchers are 
thus able to offer students a perspective to get closer to the topic and to pre­
pare their theses with non-animal methods. However, there are still only a few 
chairs in some federal states. There is need for courses of study that address 
scientific questions using new animal-free methods. So far, students in life 
sciences courses, such as biology or human medicine, must, with few excep­
tions, participate in courses that use animals. Furthermore, where platforms 
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for alternatives to animal tests have been set up, the scientists involved usu­
ally investigate 3Rs methods (replacement, reduction, and refinement), which 
means that the scarce resources are spread across all three areas. Instead, the 
platforms' financial resources need to be exclusively available for replacement 
methods. 
The situation is similar in other European Countries. There are a few na­
tional centers for alternatives to animal use, such as, the Finnish Centre for 
Alternative Methods, which teaches only animal-free replacement methods. 
In the private sector, Altertox Academy (formerly the Center for Alternatives 
to Animal Testing Academy) offers training for young scientists in replace­
ment methods. Others national centers, such as the Danish 3Rs-Center, the 
Swedish Toxicology Science Research Center, or the Romanian Center for Al­
ternative Test Methods, were founded to implement the mission of Directive 
2010/63/EU and teach not only the replacement of animal use but also reduc­
tion and refinement. The range of programs of study for animal-free methods 
( full replacement) should be expanded. It should be possible to choose courses 
of studies at European universities that will enable students to do research and 
develop methods without using animals. 
1.3 Pillar 3: Bans on Animal Testing Must Be Consolidated and 
Expanded 
Since its review in November 2017, Article 58 of Directive 2010/63/EU has bare­
ly led to sufficient improvements for laboratory animals. In the next review, the 
EC must take into account any progress made in the field of alternative meth­
ods that may lead to an end to the use of animals, in particular non-human 
primates. The first step should be to repeal Article 55 of Directive 2010/63/EU, 
which allows Member States to provide exceptions from the regulations pro­
tecting non-human primates (European Parliament, 2010 ); it also allows ex­
ceptions from Article 21 which stipulates that procedures not be performed on 
animals if they involve severe pain, suffering, or distress. Therefore, with the 
approval of the EC, Member States may, for example, use monkeys in experi­
ments that involve severe pain, suffering, or distress. 
Further bans should be introduced, including: a ban on patenting geneti­
cally altered animals; and a full ban on animal tests for household products 
and their components, including banning the sale of such goods ( analogous to 
the existing provisions for cosmetic products) is essential. 
Viable European and national competency centers should be established, 
with the following tasks: creating transparency for the public, monitoring ad­
herence to EU animal welfare law, and setting up information offices for all 
stakeholders. 
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Closer cooperation/collaboration with scientists and agencies in the us, 
which is more advanced in technological development. The us regulatory 
authorities are also not hesitant to search for and accept new animal-free 
methods. Even pharmaceutical and chemical companies think that the EC 
should be more orientated towards American models, such as the Food and 
Drug Administration (FDA) and the Environmental Protection Agency (EPA) 
(Ettel, 2018). Another example is the new Interagency Coordinating Commit­
tee on the Validation of Alternative Methods plan (National Toxicology Pro­
gram, 2018). 
1.3.1 Suggestions for Implementing Existing EU Law 
The EC Department, Directorate-General for Environment, should have a Eu­
ropean competency center, for monitoring adherence to EU law and provid­
ing up-to-date information on pain, suffering/distress, and fear as well as on 
animal-free testing methods and other information relevant to this range of 
topics. 
These additional tasks could also be integrated into existing structures, such 
as EURL ECVAM's EU Network of Laboratories for the Validation of Alterna­
tive Methods (EU-NETVAL), under the umbrella of the EC Directorate-General 
for Environment. So far, EU-NETVAL comprises laboratories in individual EU 
Member States that conduct validation studies and assess the reliability and 
relevance of new animal-free methods (EU-NETVAL, 2018). The European vali­
dation authority, EURL ECVAM, could also focus on transparency for the pub­
lic, provide information offices for all stakeholders, and monitor adherence to 
EU animal welfare law. It is also vital that a negative list be introduced that will 
stand up in court, defining tests that may no longer be conducted for ethical 
reasons. 
The establishment of national competency centers as central institutions 
for informing and educating all stakeholders involved is also necessary. At a 
national level, these tasks could be completed by the EU National Committees 
in the Member States. The national information structures established thus far, 
in accordance with Article 49 of Directive 2010/63/EU, have laid the founda­
tion for such tasks. 
The competency centers would be responsible for developing lists of criteria 
for assessing whether applications for animal experiments fulfill legal require­
ments, criteria that are lacking, thus far, but are necessary. This requires prac­
ticable assessment criteria for qualifying/quantifying the necessity, benefits, 
and ethical justifiability of the animal procedure as well as specifying the level 
of distress. The competency centers should also offer education schemes for all 
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2 
Downloaded from Brill.com11 /11 /2019 09:57:0BPM 
via free access 
HOW CAN THE FINAL GOAL OF COMPLETELY REPLACING ANIMAL 95 
stakeholders. To this end, it would be necessary to develop content and perfor­
mance records. We recommend developing an education scheme for animal­
free testing methods, analogous to the courses of the Federation for Laboratory 
Animal Science Associations (FELASA, n.d.). 
Practical, user-friendly databases should be set up to allow reliable and 
uncomplicated referencing of animal-free methods. 
The approving authorities and monitoring agencies in the Member States 
should be provided with adequate finances, expertise, and staff. 
Steps must be taken to ensure that the Member States implement the re­
quirements set out in Directive 2010/63/EU, without exception. In Germany, for 
example, although stipulated by Directive 2010/63/EU, the approving authori­
ties currently do not have a comprehensive right for evaluation when assessing 
applications for animal procedures, due to a decision made by the Higher Ad­
ministrative Court Bremen (Oberverwaltungsgericht Bremen, 2012). Directive 
2010/63/EU stipulates that project evaluation should consist of six evaluation 
points (European Parliament, 2010, Article 38, Section 2, Subsections a-f). It 
should include an evaluation of the project objectives, the predicted scientific 
benefits or educational value, and the severity of the procedures, and a harm­
benefit analysis of whether the suffering, pain, and distress inflicted on the ani­
mals is justified by the expected outcome, in light of ethical considerations and 
the ultimate benefit to human beings, animals, or the environment. 
1-4 Pillar 4: Success Monitoring of the Increase of Animal-free 
Methods and the Reduction of Animal Experiments Is of Particular 
Importance 
This pillar is especially important. It stands for the need for quality manage­
ment, as it entails control measures that systematically document the progress 
of the paradigm shift. Unlike the other pillars, there are no approaches, as yet, 
to achieve this goal; they have to be established from the start. Definitive pa­
rameters should be determined for quantifying and qualifying the reduction of 
animal experiments and the increase in animal-free methods. A retrospective 
assessment for all animal tests conducted and the publication of their data 
crucial. Directive 2010/63/EU expressly provides for such a retrospective as­
sessment (European Parliament, 2010, Article 39 ). 
1.5 Pillar 5: Complementary Measures Are Necessary 
Complementary measures comprise drastically shortening the time needed 
for assessing and approving animal-free research methods; researching ani­
mal experiment models in order to de-validate them; and introducing a class 
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action suit for animal welfare in the EU  and its Member States, as well as pro­
viding adequate resources for law enforcement authorities. 
Moving from the development of an animal-free method to its implemen­
tation in the regulatory framework, which would lead to a broader range of 
applications, has taken too long. Periods of 12 to 15 years, or even longer, have 
been a matter of course (Hartung, 2015). There is a lack of financial support 
for proof-of-concept studies as well as pre-validation and validation studies, so 
that developers spend a great deal of time seeking financial support. In addi­
tion, regulatory authorities become involved in this process at too late a stage 
(Hohensee and Bruning, 2016; Schoffl et al., 2000 ). 
According to NC ad and other researchers, there is a "growing focus on Syn­
thesis of Evidence", the experimental design and critical reviewing of exist­
ing animal models (Cronin, 2017, p. 39; NC ad, 2016a; Varga et al., 2010 ). Just as 
the new animal-free methods must be validated, it is also necessary for animal 
testing to undergo systematic review. 
Greater demand for national and international coordination of the promo­
tion and acceleration of validation, regulatory acceptance, and implementation 
of animal-free methods (NCad, 2016a). 
2 Part 2: How Has the Change of Course Been Pursued So Far­
Nationally, in the EU, and Internationally? 
Directive 63/2010/EU provides for a long-term withdrawal from all animal 
experiments. Nevertheless, for many researchers, the development of 
replacement methods has not been the priority it should be. It still has a niche 
existence. Although some research groups focus on replacement, research and 
budgets at both the national and European levels are too low and should be 
embedded in a higher-level context. Here, more efforts are necessary. 
2.1 Setting up Committees in Accordance with Directive 2010/63/EU 
With Directive 2010/63/EU, the EU  and its Member States have set the long­
term goal of ending animal experimentation and promoting the development 
of replacement methods for animal experiments. The Directive must be enact­
ed in national law by all Member States. The amended German Animal Welfare 
Act (Tierschutzgesetz) took effect in July 2013, and the new Animal Welfare Lab­
oratory Animal Regulation (Tierschutz-Versuchstierverordnung) took effect in 
August 2013. However, while opportunities for achieving a higher level of ani­
mal protection should have been put in place, they were forfeited. Although 
the necessary legal basis exists in primary law, a maximum limit for pain or suf­
fering in animal experiments, and a ban on increasing animal experiments, by 
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eliminating the exemption clauses, were not enforced in German law (Peters 
and Stucki, 2012 ). Furthermore, the comprehensive right of project evaluation 
pursuant to Article 36 of Directive 2010/63/EU was not implemented and was, 
instead, replaced by a qualified plausibility check (Hildermann, 2015). 
Article 49 of Directive 2010/63/EU states that all EU Member States must 
establish National Committees for the protection of animals used for scien­
tific purposes (European Parliament, 2010 ). In Germany, this role is performed 
by the Federal Institute of Risk Assessment (Bffi), which has established the 
German Centre for the Protection of Laboratory Animals (Bf3R), located at 
the Bffi, as set out in the amendment of the German Animal Welfare Act that 
took effect on July 13, 2013 (Bffi, 2017b ). According to Paragraph 45 of the Ger­
man Animal Welfare Laboratory Animal Regulation, the National Committee 
advises the competent authorities and animal welfare committees on matters 
regarding the acquisition, breeding, accommodation, or care of vertebrates 
and cephalopods ( as defined in Paragraph 11 Section 1 of the Regulation); or the 
use of vertebrates and cephalopods in animal experiments. The National Com­
mittee also advises the competent authorities, in accordance with Paragraph 
46 of the Regulation, on matters regarding alternatives to animal experiments 
(Bundesministerium fur Justiz und Verbraucherschutz, 2017). 
The German Centre for the Protection of Laboratory Animals (Bf3R) was 
founded in the context of the animal welfare initiative ("Tierwohlinitiative") 
of the German Federal Ministry of Food and Agriculture (BMEL ) in 2015. 
While before the establishment of the Bf3R, the Centre for Documentation 
and Evaluation of Alternatives to Animal Experiments (zEBET )  was of central 
importance, it has now been integrated into the Bf3R as one of five areas of 
competence. The competence areas are research and development of meth­
ods to reduce pain and suffering of laboratory animals (refinement); the Na­
tional Committee; development of alternatives in the field of toxicology; and 
coordination of research funding. The last two areas of competence were 
formerly tasks of ZEBET. However, the tasks of all competence areas are pre­
dominantly performed by Experimental Toxicology and ZEBET (Bffi, 2017b ). 
Therefore, alternative methods are investigated, developed, and validated in 
accordance with the 3R principles. Thereby, the focus has shifted from the de­
velopment of replacement methods for animal experiments towards the 3Rs. 
Today, refinement and reduction of animal use is treated of, at least, equivalent 
importance. 
2.2 Has Funding Been Increased in Recent Years? 
2.2.1 Funding on a National Level (Germany) 
Although an increasing number of projects are funded on a national level, those 
who conduct research in replacement methods criticize that disproportionate 
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funding for animal experiments and an exaggerated perception of their im­
portance has led to a decades-long neglect of the development of replacement 
methods and a reticence to promote them actively (Baumgartl-Simons, 2017; 
Leist, 2016). 
2.3 Programs for the Development of Animal-free Methods: The Funding 
Has to Be Shared with Refinement Methods 
In Germany, projects are funded mostly by the German Federal Ministry of 
Education and Research (Bundesministerium fi.ir Bildung und Forschung, 
BMBF ).  BMBF, Bf3R, and the set Foundation together provide approximately 
€5. 7 million per year in funding for research into the development of replace­
ment and complementary methods for animal experiments based on the 3R 
principles. A few German federal states have established funding programs of 
their own, including Baden-Wiirttemberg, which provides €400,000 per year; 
and Rhineland-Palatinate, €701000 every two years (see Table 3.1). Some in­
dividual projects, such as postgraduate programs, are funded by the German 
research association, D F G ;  however, this funding is not dedicated to the devel­
opment of animal-free methods and, therefore, is not listed here. 
Note: This table presents an overview, not an official empirical survey. 
On a state level, in Germany, it seems that an expansion of research asso­
ciations and professorial chairs has slowly begun. Some federal states have 
established research associations or professorial chairs and are providing ini­
tial funding for a finite period. For example, Baden-Wiirttemberg funds the Do­
erenkamp-Zbinden Chair of in vitro Toxicology and Biomedicine/Alternatives 
to Animal Experimentation with €200,000 to €400,000 annually. However, 
most of this funding is combined with research for the 3Rs as a whole, so fund­
ing for replacement methods alone cannot be quantified. For example, Berlin 
may soon take over the Berlin-Brandenburg research platform (BB3R), with 
an integrated postgraduate program; and it plans to establish an institute for 
alternatives to animal experiments, with €8.6 million, at the Charite Univer­
sity School of Medicine Berlin (Der Regierende Biirgermeister-Senatskanzlei 
Berlin, 2017 ). The current BMBF funding has expired and negotiations for fund­
ing on a state level are currently in progress. In Frankfurt, a professorship for 
pharmaceutical technology has been established, with 3R methods as its main 
research focus. During the next five years, €200,000 will be made available to 
be shared with another chair for refinement methods. Lower Saxony finances 
the research initiative R2N-Replace and Reduce, with €4.5 million. North 
Rhine-Westphalia is funding the Centrum fi.ir Ersatzmethoden zum Tierver­
such ( CERST-NRW), a center for replacement methods for animal experimen­
tation, with €500,000 per year for a period of five years. 
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TABLE 3 . 1  Funding for the development of  animal-free methods in Germany 
A. Chairs and platforms 
Federal state Subject 
Baden- Chair 
Wiirttemberg 




Lower Saxony Research 
Association 
North Rhine- Chair 
Westphalia 
Designation Amount (€) Financed by 



























( C E RST-NRW) 
400,000 per Wiirttemberg 
annum 
92,000 Federal 
(20 1 4-2 0 1 6),  Ministry of 
negotiations Education 
at state level and Research 
to continue (BM B F )  
200,000 per Hesse/ 
annum (5 Johanna 
years) Quandt 
Foundation 
4.5 million ( 4 Lower Saxony 
years) 
500,000 per North Rhine-
annum Westphalia 
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TABLE 3 . 1  Funding for the development of  animal-free methods in 
Germany (cont. ) 
B. Project funding 
Germany-wide Development, Approaches 
proof-on- for the 
















Baden- Development, Development of 400,000 per Baden-






Development, Development of 70,000/24 
proof-on-conceptreplacement and months 
complementary 




Since 1981, the BMBF has funded 530 projects for the development of 3R meth­
ods (BMBF, 2016). The annual budget totals €5 million (although applicants 
for funding from this BMBF research budget, and for research prizes awarded 
for the development of alternatives to animal experiments, include develop­
ers of refinement methods for animal experiments, i.e. animal experimenters). 
So far, more than €170 million in funding has been provided in this area (Ho­
hensee and Bruning, 2016). However, a 2011 study published by the Fraunhofer 
Institute for Systems and Innovation Research showed that about 30 per cent 
of the projects funded between 1981 and 2000 focused on refinement (Hiising 
et al., 2011). In addition, few institutions or projects receive sufficient funding. 
For example, the BfR simultaneously supports about ten working groups for 
up to three years, each with an average of €35,000 per year. By comparison, the 
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development of the in vitro pyrogen test required €6 million from development 
to implementation. The working group needed €400,000 per year (Thomas 
Hartung, personal communication, August 2016). Numerous applicants com­
pete for the low project funds. The funding amount of about €5.7 million from 
the BMBF, set foundation, and Federal Institute of Risk Assessment is far too 
small, with no budget available for pre-validation and validation studies. Since 
the developers of refinement methods can also apply for these funds, even less 
money is available. Funding for refinement methods should have its own bud­
get. The half-hearted funding is intended to give the impression that Germany 
actively supports the development of new animal-free methods. However, it is 
not an expression of the decision to phase out animal experiments, instead, it 
slows down the development. 
2.4 Additional Programs 
There are a few complementary funding programs to the main program, 
Alternatives to Animal Experiments, such as e:Bio-Innovative Competition 
Systems Biology, which runs until 2020. Systems biology unites complex high­
throughput experiments with mathematical modeling of the obtained data, 
to develop models to predict complex biological processes on cellular, tis­
sue, and organ levels as well as in the entire organism (BMBF, 2011). One of 
the complementary programs, BioOkonomie 2030-GO-Bio, aims to further 
develop innovative research topics in the field of life sciences to the point 
of making these available for economic implementation, like innovative 
start-ups (Bundesministerium filr Wirtschaft und Energie, 2017). This is in­
teresting for organ on a chip technology developments intended for market 
launch. 
2.4.1 Funding Transregional/On a European Level 
There are also a few programs financed by more than one EU Member State, 
such as InnoSysTox-Innovative Systems Toxicology for Alternative to Animal 
Testing, a €3 million project financed jointly by Germany and the Netherlands 
(ZonMw, 2017). The application deadline was December 2014. Another pro­
gram is the translational funding initiative, Multilateral Collaboration in 
Computational Neuroscience: Germany-US-Israel-France ( BMBF, 2015a ). 
The EU-wide budget is unknown. In Germany, €901000 - €225,000 in fund­
ing was available for a three-year term. The application deadline for the first 
run was November 2016. However, as previously noted, across the EU there is 
currently only one program financed by the Eu's funding framework Horizon 
2020 dealing with animal-free issues, EU-ToxRisk, which deals with feasibility 
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studies for methods that most urgently need to be developed in toxicology. In 
EU-ToxRisk, 39 project participants must share a budget of €30 million. 
The research guidelines that define what methods are most urgent are set 
out by the scientists themselves, and not by the EC. This was the case with proj­
ect cluster SEURAT-I (SEURAT-I, 2013), which received €25 million in funding 
from both the EU and the industrial association, Cosmetics Europe. Cosmetics 
Europe also contributes to the funding for EU-ToxRisk (amount unknown) 
( Cosmetics Europe, 2017 ). Especially urgent areas of research should be stipu­
lated, and the development of animal-free methods must have priority. At the 
EU level, scientists seem to agree on the methods in most urgent need of de­
velopment; but in Germany, there is no agency that decides which methods 
need to be developed and provided with preferential funding. Apparently, a 
particular bone of contention is whether it is better to fund all research in­
discriminately, in the spirit of scientific freedom or originality, or to demand 
specific research into solutions for important questions (Hohensee, 2015). In 
the case of achieving the end goal of full replacement, as set out in Directive 
2010/63/EU, the answer is clear: Research developments should not be funded 
indiscriminately, but rather clear priorities are necessary, with replacement of 
foremost importance. 
2.4.2 Funding on an International Level 
The us was the first country to take decisive steps towards ending animal ex­
periments, with the concept Tox21 (National Center for Advancing Transla­
tional Sciences, NCATS, 2017a). Toxz1 is a collaboration among the NIH, FDA, 
EPA, and the National Toxicology Program at the National Institute of Environ­
mental Health Sciences, with the goal of achieving better assessment of the 
toxicity of substances by using faster and more efficient human-specific meth­
ods in high-throughput technologies. To this end, fit for-purpose cell models 
have been developed; and a high-throughput apparatus has been set up, which 
scans the gene expressions in human cells for alterations after they have been 
exposed to the test substance. The EPA has established its own National Cen­
ter for Computational Toxicology, in which prediction models are developed 
based on the new results ( Committee on Toxicity Testing and Assessment of 
Environmental Agents, 2007; NCATS, 2017b ). 
A number of organ on a chip start-ups, most of them from the us, have 
been established to produce lab-scale prototypes. Zhang and Radisic ( 2017) de­
scribed the most important 29 start-ups, dividing their work into groups: start­
ups developing barrier functions, start-ups developing tissue-interface on a 
chip, and start-ups developing parenchymal-tissue on a chip. The first scientist 
to envision the possibility and pioneer the practice of quantitatively-simulating 
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molecular and cellular biological systems, with in vitro devices was Profes­
sor Michael L. Shuler of Cornell University, New York (Hurelcorp, 2018). To­
gether with Professor James J. Hickman of the University of Central Florida, 
Shuler founded the start-up, HESPER0S,  in 2014 (HESPEROS ,  2017). Hickman 
developed the first serum-free media for hippocampal neuron cultures in 
1995 (Schaffner et al., 1995) and published the first readouts of electrical and 
mechanical functions of neurons in 1998 (Ravenscroft et al., 1998). Together 
with Shuler and others, Hickman integrated cardiac, muscle, neuronal, and liv­
er modules in a microphysiological system, under continuous flow conditions 
in a serum-free defined medium, utilizing a pump-free platform (Oleaga et al., 
2016). So far, HESPER0S has successfully tested six organs on a chip (Miller, 
2017). 
TissUse, a German spin-off from the Technical University of Berlin, was 
founded by Dr. Uwe Marx in 2010. The initial focus of this company was on 
the development of two-organ and four-organ models. Today, like HE SPEROS,  
their ultimate goal is to develop a human on a chip, integrating at least 10 or­
gan-like tissue constructs of human origin. Instead of using a gravity-driven 
flow, like Hesperos, the TissUse platform contains a built-in micropump, driv­
en by an external pneumatic controller. A second microfluidic circuit ensures 
drainage of the fluid excreted through a kidney's epithelial cell layer. The four­
organ chip with intestine, liver, skin, and kidney is already available and can 
be co-cultured for up to 28 days (Maschmeyer et al., 2015). The Wyss Institute 
for Biologically Inspired Engineering at Harvard University in Boston has pro­
duced 19 university start-ups (Wyss Institute, 2018) and is known for its organ 
on a chip developments. One of the current research results is a pulmonary 
thrombosis model on a chip. The research was co-financed by the Defense Ad­
vanced Research Projects Agency (DARPA), Janssen Pharmaceuticals (Jain et 
al., 2018), and funding from NCATS (NCATS , 2018). 
The Center for Alternatives to Animal Testing ( CAAT) was founded in 1981 by 
Alan Goldberg, a professor at Johns Hopkins University in Baltimore. CAAT was 
then financed by the American Cosmetic Toiletry and Fragrance Association 
(CTFA), which was interested in the development of replacement methods 
for testing their products ( CAAT, n.d. a). CAAT's goal is to create fundamental 
knowledge regarding possible methods for replacing tests using whole organ­
isms (i.e. living animals) with alternative methods in the development and 
testing of commercial and therapeutic products. CAAT established its own 
in vitro toxicology laboratory in 1985. In 1988, the cosmetics company, Avon, 
financed the first program for replacing animal experiments in the field of con­
tact allergies. Since 1989, CAAT has also been supported by government agen­
cies and, as of 1992, by the EPA. CAAT-Europe, at the University of Konstanz in 
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Germany, the European equivalent to CAAT in the us ( CAAT-US ), was founded 
in 2009. CAAT coordinates transatlantic relations between the us and Europe 
in the field of animal-free methods, by bringing together international stake­
holders in congresses and workshops on various topics of non-animal research 
(Universitat Konstanz, 2018). On information days, the public is informed 
about the latest developments in this field. Both CAAT-US and CAAT-Europe 
in Germany train young scientists in new animal-free methods ( CAAT, n.d. b ). 
Expanding education and research towards science without animal 
experiments is crucial, as only a small group of researchers currently work on 
replacement methods. Despite the aforementioned funded individual profes­
sorial chairs, there is still no way of completing a course of studies that would 
equip students with the professional capacity to develop alternatives to ani­
mal experiments. In order to complete a thesis at one of the newly established 
chairs ( see above), the student must first have studied one of the more common 
courses of studies, such as biology, medicine, veterinary medicine, biochemis­
try, pharmaceutics, toxicology, or biophysics, which, for the most part, contin­
ue to use animals for training ( SATI s, 2017a ). Only very few tertiary institutions 
allow the use of alternatives to animal dissection on ethical grounds. Instead, 
tolerance towards alternatives to the use of animals in training courses has 
decreased, depending on the course organizers' attitude. Only four German 
State Higher Education Acts (North Rhine-Westphalia, Hesse, Saarland, and 
Bremen) allow the right to decline using animals on ethical grounds (SATI S ,  
2017b ). Most students quickly get used to using animals because they do not 
want to belong to a fringe group, without prospects of gaining a professional 
foothold, or they want to keep their options open. The lack of opportunities 
for attaining qualifications in animal-free courses of studies leads to a lack of 
qualified young scientists in the area of animal-free methods, so that fund­
ing bodies sometimes argue that the reticence in providing finances results 
from insufficient scientific standards (Hohensee, 2015). The lack of political 
will means that the subject continues to go in circles. 
2.5 The Time-consuming Validation Process 
The time taken for the validation and approval of animal-free testing meth­
ods urgently needs to be shortened. The broadening of funding by the BMBF 
program, Alternatives to Animal Testing, to include strategies for imple­
menting newly developed methods as replacements for animal experiments 
(BMBF, 2015b, Module 1 1), is a first step in the right direction; but it is by no 
means enough. Validation studies, in particular, are extremely expensive and 
time-consuming and go through the bottleneck of the European validation 
authority, EURL ECVAM, which has limited capacities. There are simply not 
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enough resources. If a validation study is successfully conducted, the process 
of recommendation by EURL ECVAM begins with consultations with different 
committees, including the Preliminary Assessment of Regulatory Relevance 
(PARERE) and the EURL ECVAM Stakeholder Forum (ESTAF) (EURL ECVAM, 
2017b ). EURL ECVAM then consults with other EC committees, as well as the 
other international partners for validation and cooperation on the develop­
ment of alternative test methods. The general public and companies, who 
would ultimately implement the development, are given time to submit com­
ments. Only after a long period of time is a Test Guideline drafted, and the 
method is then included in the annexes of the relevant statutory regulation. 
This sometimes requires 10 years (Hohensee, 2016a). There are, however, in­
stances where the inventor is not interested in validation because it would tie 
up resources; for example, Ulrich Stock, who developed a borosilicate chamber 
with a blood-like solution to test heart valves under human-like conditions in 
2011 (personal communication, November 2011). Here an agency is needed to 
oversee proceedings. 
3 Part 3: Why Are There Insufficient Animal-free Test Methods and in 
Which Areas? 
3.1 In Which Areas Are There Insufficient Animal-free Test Methods and 
Why? 
In this section, we focus on the field of toxicology alone. Relevant animal-free 
methods in the field of toxicology could also be applied to other areas. There 
has been great progress in the development of replacement methods in the 
area of local toxicity testing ( e.g., skin and eye tests), where many animal ex­
periments have already been replaced (AltTox, 2016). However, there are still 
no replacement methods for long-term studies of the organism as a whole, for 
example, in the area of inhalation toxicity or tests for reproductive damage 
and damage caused to offspring. The development of replacement methods 
for testing environmental toxicity is also only rudimentary. 
The goal of the holistic approach is to be able to depict the entire organism 
in a simplified and miniaturized form. This is a complicated process because 
individual organs, their biology, and their interactions within the body are 
highly complex. In order to replace this complex organism in experiments, sci­
entists aim to create a human on a chip, in which all the vital human organs 
are combined on a chip of miniaturized scale of about 1:10,000. At present, 
about eight miniaturized organs can be simulated and interconnected (Ingber, 
2017 ). However, to construct a human surrogate for drug screening, scientists 
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are convinced that it will not be necessary to replicate a perfect human body 
but simply to provide a better predictive model than animal models (Wang 
et al., 2016) .  For such simplified models, many different technical approaches 
have been developed; for example, according to chip fabrication techniques, 
medium composition, delivery systems of media, nutrients, oxygen, metabo­
lites, and so forth, have a strong influence on the quality of cell or organ cul­
tures and the results. Wang et al. (2016) provide an exploratory overview of 
current developments in multi-organ systems and their pro and cons. Since 
each start-up presently holds only a piece of the entire puzzle, the authors 
recommend that the multiple companies should be motivated to join forces to 
combine their techniques and patents, thereby fostering the continued evolu­
tion of more advanced products. In many cases, the viability of organoid sys­
tem cultures cannot, currently, be guaranteed for long-term investigations. 
Depending on the laboratory, there are groups whose cell systems can be 
utilized for just one week (Hohensee, 2017) and others for three months (Epit­
helix, 2017 ). These differences may result from the organs' different needs and 
the difficulties of recreating miniaturized human organs, especially in the case 
of such vital organs as the liver or kidneys. Wang et al. (2016) discuss the need 
for a common culture medium, with full chemical definition, as a blood sur­
rogate that can maintain the viability and function of various organ models 
and by the use of extracellular matrices can influence the reproducibility and 
physiologically-realistic ratio of liquid to cell volumes in the (multi-) organ on 
a chip system. 
Methods in the field of inhalation toxicology are advanced with superficial 
and deeper respiratory epithelium in vitro and with, in some cases, a viability 
or usability of more than a month (Epithelix, 2017).  Lung models have been 
in use for quite some time (Esch, Bahinski and Huh, 201s; Huh et al., 2010 ) .  
One method, having achieved general approval, is currently undergoing a 
validation study in Germany (Hoffmann et al., 2017) .  However, it was initially 
intended for replacing animal experiments in the area of acute toxicity. Devel­
opments in the area of long-term toxicity are not as advanced and are being 
explored in a feasibility study within the framework of the EU project cluster, 
EU-ToxRisk (EU-ToxRisk, 2016).  
Recreating a reproductive tract in a multifluidic system is a particular chal­
lenge. Some advancements have already been made, such as the develop­
ment of 3D cell culture models of animal Fallopian tubes, in which embryos 
can even develop in the "tubular fluid" ( Chen et al., 2017 ) .  There are models 
of the vagina and in vitro test systems with ectocervical cells and fibroblasts, 
which have been developed to test substances for their irritant, toxic, or endo­
crine disruptive effects (Ayehunie et al., 2016; Landry et al., 2016) .  An artificial 
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reproductive cycle has also been created, using murine ovarian follicles in vi­
tro, to investigate the mechanisms of reduced fertility (Zhu et al., 2016). First 
steps have been taken to culture parts of female ovaries, using human follicles, 
to study the maturation processes (Laronda et al., 2014). There are also initial 
developments for studying the hormonal cycle, using human ovarian tissue as 
well as mice and human follicles (Skory et al., 2015). More advanced is a system 
(EVATAR) to simulate the 28-day hormone profile of the female reproductive 
tract to study its influence on reproductive tissue (Xiao et al. 2017 ). However, 
due to species differences between mice and humans, the use of murine tissue 
can only be a first step. The goal is to construct models with human-specific 
tissue material (for an overview see Eddie et al., 2015). A repro-on a chip could 
be used in the future to recreate mechanistic developments and disorders in 
the development of the reproductive organs in the field of basic and applied 
research but not reproductive behavioral disorders or detrimental effects on 
offspring. Other solutions would have to be found for these. The project cluster 
EU-ToxRisk is also conducting feasibility studies in the field of developmen­
tal and reproductive toxicology (EU-ToxRisk, 2016). Unfortunately, hormonal 
regulation ( feedback loops with hypothalamus, adenohypophysis, and thyroid, 
which affect the tissues) and immune defense, which would allow the modula­
tion of a miniature human on a chip, are lacking. 
What is appealing about this human on a chip technology is that automa­
tion could rapidly shorten the time and cost of development by using large 
rooms filled with robotic systems to simultaneously run tests on a multitude 
of chips, with different concentrations of a variety of substances, without the 
disruption of human factors ( e.g., introduction of bacteria, measuring errors, 
or pipetting errors). This would facilitate more targeted, cheaper, and faster 
development and production and make it more attractive for industry. 
3.2 Why Aren't Developments Progressing More Quickly in Germany? 
The development of animal-free methods primarily depends on the advance­
ment of knowledge (Linz School of Education, 1999; Schmiel, 2006) as well 
as other factors, such as efficient methods of investigation and measurement, 
high-performance research facilities with a workplace environment conducive 
to creativity, innovative staff, and, most significantly, sufficient funds. The fol­
lowing observations regarding these factors are restricted to Germany. 
3.2.1 Powerful Methods of Investigation and Measurement 
Modern molecular biological and biochemical methods, insights into cell cul­
ture, stem cell research, chip technology, omics technologies, computers of 
high performance, algorithms, potent imaging techniques, and bioprinters 
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have considerably advanced the development of animal-free testing methods 
( BM BF, 2016; DFG,  2017 ). While these powerful methods should also be available 
to universities and other research facilities, they would involve considerable 
cost. Several facilities are currently known to need money for 3D bioprinters in 
order to advance research on non-animal replacements, including the Institute 
of Veterinary Anatomy of the Free University Berlin. It is possible that some 
research remains at a certain level of development due to lack of instruments. 
This situation has been recognized by the German Research Foundation (DFG,  
2017 ) .  The problem could be addressed by establishing decentralized method 
centers, whose services would be available to all authorized research institutes. 
Collaborations with extramural institutes ( e.g., Fraunhofer Institutes) also 
need to be facilitated and, perhaps, expanded. 
3.2.2 High-performance Research Facilities with a Workplace 
Environment Conducive to Creativity 
In addition to up-to-date research topics, the workplace environment is also 
important for the research staff, for example, in terms of hierarchy, recogni­
tion, and interdisciplinary collaboration. Recent years have seen progress 
in this regard. New university courses have also been introduced, some of 
which are suitable for the development of replacement methods for animal 
experiments, such as Medical Biotechnology (Technische Universitat Berlin, 
TU-Berlin, 2017), Biomedical Computing (xStudy S E, 2017a), Life Science En­
gineering (Hochschule fur Technik und Wirtschaft Berlin, HTW-Berlin, 2017), 
Biomedical Engineering (xStudy S E, 2017b ), and Biochemistry and Molecular 
Biology (Universitat Bayreuth, 2018). There are increasingly more student ex­
changes between international partner universities (xStudy S E, 2017a). 
3.2.3 Innovative Staff 
Understandably, aspiring students and postgraduates, among others, are in­
fluenced by their career prospects when choosing suitable fields of study. This 
choice involves assessing how much return they can actually get on their in­
vestment in their course of studies. The best employees go to institutes with 
the best reputations ("everyone wants to go to Harvard"); institutes that do the 
best research, who are best known, that have significant influence in the sci­
entific community, that are not economically threatened, and that pay their 
staff well. For this reason, attractive degree courses in the area of animal-free 
methods are needed ( e.g., Medical Biotechnology at TU-Berlin). There should 
also be a climate of internationality, enabling an exchange of know-how and 
strategic thinking in problem solving. At present, there are professorial chairs 
in Germany, where one can learn animal-free research and testing methods; 
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however, entire courses of studies are not available. Students often must work 
with animals or animal organs because they must first complete a standard 
syllabus ( e.g., biology), after which they can attend single courses or com­
plete their theses at the newly installed chairs, in places such as Frankfurt, 
Diisseldorf, and Konstanz (Buchmann Institute for Molecular Life Sciences, 
2017; Hohensee; 2016b; University of Konstanz, 2018). 
3.2-4 More Capital from the Corporate Sector Is Necessary 
Sufficient capital is important. The development of animal-free test methods 
in Germany is largely financed by state funding. This means that the risks in­
volved with research and development are borne by society (taxpayers), whilst 
the returns on successfully developed technologies benefit all stakeholders. It 
would, therefore, make sense to provide not only national and European fund­
ing but also more capital from the corporate sector. European organizations, 
such as Cosmetics Europe and the European Partnership for Alternative Ap­
proaches to Animal Testing (EPAA), are good examples (Cosmetics Europe, 
2017; EPAA, 2017). Tax relief for companies that invest in research has been de­
manded for many years and should be implemented (Ver band der Chemischen 
Industrie, 2017). In the us, there are more ambitious programs leading to bet­
ter and more innovative scientific outputs. NCATS at NIH and DARPA recently 
funded a us$150 million program for grants in the field of toxicity testing, drug 
efficacy evaluation, and disease modeling (Wang et al., 2016). It seems that 
there is a strong motivation to make the new systems successfully applicable. 
In Europe, there are no such programs available. Funding programs are frag­
mented into small individual measures with much smaller budgets. So far, only 
the Netherlands has clearly expressed its intentions. Other Member States are 
reserved, expressing themselves at best behind closed doors and referring to 
their cooperation within the framework of their National Committees. Many 
researchers who use animal methods likely have little interest in the success of 
the Dutch plan. Such reservation by Member States could be a barrier towards 
the success of the plan. 
4 Part 4: The Netherlands Makes a Name for Itself 
4.1 Why Is the NC ad Report a Good Template for a Paradigm Shift? 
As of May 2017, NCad has published 108 documents, demonstrating its suc­
cess (NCad, 2016a); however, the Netherland's former Minister of Agriculture, 
Martijn van Dam, ambitiously pursued "the final goal of full replacement" as 
set out in Recital 10 of Directive 2010/63/EU (European Parliament, 2010 ). The 
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manner in which Dutch politics has responded to the initiative is truly sen­
sational. On April 8, 20161 the Dutch Minister of Agriculture requested that 
NCad Chairman, Herman Koeter, develops a phase-out timeline for proce­
dures involving animal use. The plan, Transition to Non-Animal Research, was 
published on December 15, 2016 (NC ad, 2016a). The history of its development 
is as interesting and groundbreaking as the plan itself. 
4.2 The Development of the NCad Report 
The NCad plan is not the result of a whim but rather the product of years 
of expert preparation, in which all stakeholders were involved. In June 2014, 
the Dutch Ministry of Economic Affairs commissioned the expert group, The 
Think Tank on Supplementary Financing for Alternatives to Animal Testing 
(De Denktank Aanfullende financierung alternatieven voor dierproeven), to 
develop recommendations for additional funding for the development of "in­
novations without laboratory animals" (NCad, 2016a, p. 42,). The Think Tank 
presented its 140-page report, In Transition! The Netherlands leads the way in 
laboratory animal-free innovations, in October 2015 (Henneman et al., 2015). 
Based on this report, on April 8, 20161 the Minister of Agriculture, Martijn van 
Dam, assigned NC ad the task of presenting a strategy for phasing out animal 
procedures. Van Dam specified that the strategy should involve the National 
Institute of Public Health and Environmental Protection (Rijksinstituut voor 
Volksgezondheid en Milieu Netherlands, RIVM ). RIVM has significant exper­
tise in toxicity testing and is both national and international coordinator for 
3Rs methods. van Dam instructed NCad to name specific phasing-out targets 
and stated that the legally required toxicity tests should be phased out within 
10 years, which would reduce the number of animals used in experiments by 
10% in the Netherlands. He also emphasized the goal, formulated in the Think 
Tank's recommendations, that the Netherlands become the world leader in 
laboratory animal-free innovations by 2025 (NCad, 2016b ). 
NCad conducted two expert workshops on June g and July 7 1 2016 in co­
operation with the RIVM (NCad, 2016a, p. 13). In August 20161 the Linkedin 
group, Towards a Future of Scientific Progress Without the Use of Experimental 
Animals, was founded (Koeter, 2016). As of November 17, 2016, the group had 
245 members, but unfortunately it delivered little of substance (NCad, 2016a, 
p. 51). A public consultation was held on September 8, 2016 in Den Haag, where 
a broad range of organizations commented on specific recommendations, 
such as "It is possible to move away from the regulatory animal procedures 
within the next ten years" (NC ad, 2016a, p. 51). The report, Transition to Non­
Animal Research, was presented to van Dam and published on December 15, 
2016. 
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4.3 What Facts and Figures Are Named in the Phase-out Timetable? 
In its report, NCad divided animal experiments into different areas and as­
sessed the possibility of reducing them by 2025. The Netherlands aims to be an 
international leader in the field of innovation without laboratory animals by 
2025 and sees a realistic chance of achieving this goal. Areas and possibilities 
of reduction, as noted in the NCad report, are: 
1. Regulatory tests: 
- "The use of laboratory safety testing for chemicals, food additives, pes­
ticides, and (veterinary) medicines can be phased out by 2025 whilst 
maintaining the existing safety level" (NCad, 2016a, pp. 3, 17). 
- "The use of laboratory animals in regulatory tests for the release of 
biological products, such as vaccines, will be phased out by 2025 whilst 
maintaining the existing safety level" (NCad, 2016a, pp. 17-18). 
- Regulatory preclinical tests associated with the registration of new 
biological substances/products cannot be phased out by 2025. "At this 
stage, however, due to the complex composition of these products and 
generally complex mechanism of action, the regulatory preclinical 
research associated with the registration of new biopharmaceuticals 
( such as vaccines or monoclonal antibodies) cannot be phased out at 
the same pace" (NCad, 2016a, pp. 17-18). 
2. Basic scientific and medical research: 
- Animal experiments in the field of "curiosity-driven basic research 
cannot be phased out by 2025. Therefore, individual ten-year plans are 
necessary for each area of research" (NCad, 2016a, p. 15). The complex 
procedures and interactions in an organism as a whole cannot be sim­
ulated at the current time. 
- "Within the field of fundamental scientific research, the reduction or 
phasing out of the use of animals is not realistic in the short term in all 
areas of research" (NCad, 2016a, p. 18). 
3. Applied and translational research: 
- While animal experiments in applied and translational research (im­
plementation of preclinical research in clinical development) cannot 
be phased out by 2025, the development of replacement methods can 
be accelerated. This includes investing more in human-specific mod­
els and less in animal models. The Netherlands aims to become "an 
international leader" in this respect (NCad, 2016a, p. 19 ). 
4. Education and training: 
- "By focusing on animal-free practices and actively reflecting on the use 
of laboratory animals in education, the use of laboratory animals for ed­
ucation and training can be significantly reduced" (NC ad, 2016a, p. 19 ). 
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4-4 Transition Objectives, Transition Strategy and Management of the 
Transition 
NCad has found that there is a realistic chance of completely phasing out 
animal experiments in the areas of regulatory safety tests ( for chemicals, 
food additives, pesticides, and veterinary and human medical products) and 
regulatory tests for the release of biological products ( e.g., vaccines) by 2025. 
This requires a transition strategy and management of the transition. The de­
velopment will not take place on its own. Therefore, we strongly recommend 
the development of NCad's transition objectives, transition strategy, and pro­
gram for transition management. 
441 Transition Objectives 
The transition objectives refer to a paradigm shift away from existing mind­
sets and practices, which are combined with animal use, to a strong focus on 
innovations without laboratory animals. In regulatory research, this means a 
significant reduction in the use of laboratory animals; in the field of basic re­
search, the development of a ten-year vision for each area; and in the field of 
applied and translational research, more rapid progress, for example, through 
the development of human models for human diseases. Furthermore, the use 
of animals in education and training can be significantly reduced (NC ad, 2016a, 
pp. 3-4). 
442 Transition Strategy 
NC ad has stated that the following is necessary for a good transition strategy: 
- the use of human data 
- international cooperation for a new approach to risk assessment 
- multidisciplinary cooperation on the development and approval of replace-
ment methods 
- monitoring of the evaluation and dissemination of replacement methods 
- monitoring and evaluation of the reduction of animal procedures ( since 
the contribution replacement methods make towards the reduction of the 
number of animals used in the Netherlands cannot currently be proven) 
- development of an innovation index for replacement methods ( data 
warehouse, directory) in collaboration with other countries (NCad, 2016a, 
p. 24). 
443 Transition Management 
The NCad report states that the key to success is (international) collaboration 
among all stakeholders. The Minister for Agriculture would have the guiding 
role but also involve other ministries. The existing Interdepartmental Working 
Group on Alternatives to Animal Procedures would be transformed into an 
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Interdepartmental Management Group, with the involvement of representa­
tives from several ministries. The Management Group would draft an agenda 
for the new replacement methods that need to be developed in consultation 
with all stakeholders. 
4.5 Evaluation and Conclusions 
An analysis of the 108 reports that led to the decisions presented in the NCad 
report, showed that the phase-out timeline is not an unrealistic idea. The 
phase-out timeline is based on the results of two years of intense consultation 
and work, involving representatives of stakeholders from the fields of science, 
applied research, contract research, laboratory animal science, medicine, 
replacement of animal testing, and animal welfare (NCad, 2016c, p. 2). The 
phase-out timeline was developed with all participating groups; as such, the 
road map is certainly ambitious but by no means unrealistic. It is, therefore, 
disconcerting that other EU Member States have either ignored or rejected the 
Dutch plan, and none have expressed support. 
5 The Way Forward 
What has to be done to rigorously pursue the "phasing out of animal proce­
dures and the stimulation of innovation without laboratory animals" (NCad, 
2016a, p. 3)? With the NCad report, Transition to Non-Animal Research, the 
Netherlands has not only presented an opinion but has developed a con­
cept for purposefully affecting a paradigm shift. The NCad report contains 
clear transition objectives, a transition strategy, and a program for transition 
management. Our association, People for Animal Rights Germany, proposes 
that the following can be achieved, based on the Dutch concept and includ­
ing our five pillars and our demand for a master plan for phasing out animal 
experiments: 
The EU Member States' National Committees (European Parliament, 
2010, Article 49) should endorse the N Cad plan. The national responsible 
ministers ( especially the ministers responsible for the animal welfare, 
science, and research portfolios) should advocate for the adoption of the 
NC ad concept, to encourage the governments of the Member States to 
implement the Dutch plan in their own countries. Parallel to this, we rec­
ommend that the responsible national ministers vote in their respective 
Councils of Ministers to support the NC ad plan at an EU level. 
Based on the national governmental resolutions and the resolutions of 
the EU Council of Ministers, the EC should adopt the NC ad concept as a 
principle for action for reducing animal testing and funding animal-free 
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procedures. Political action is also urgently needed to stop the different 
stakeholders working against each other. 
These objectives can be achieved by the EU Members States' ministers 
responsible for the animal welfare, science, and research portfolios, by 
developing a new approach to assessing the risks posed by substances 
and asserting this internationally beyond the EU. The pivotal issue is the 
actual risk (risk assessment) and not the substances' overall hazard po­
tential (hazard assessment) (NCad, 2016a, p. 20). 
In the short term, the Netherlands intends to compile a priority list for 
areas of regulatory testing that lack animal-free methods. Other EU 
Member States should actively support the Netherlands in compiling this 
list. The EU Member States and the EC should then approve funding pro­
grams for these procedures. Funding programs should only be available 
for animal-free testing methods and provide continuous funding, from 
development to final validation. 
It is necessary that the responsible ministers in the EU Member States 
optimize the validation process. The results of methods to be validated 
must be compared with human data and not with data from animal ex­
periments (NCad, 2016a). The time needed for the validation process 
should also be shortened. 
The responsible ministers in the EU Member States should agree on the 
introduction of a monitoring system for quality assurance during the 
transition process, which would monitor the development and applica­
tion of animal-free procedures and the phasing out of animal procedures, 
allowing timely intervention in the case of negative developments. 
The Dutch Minister of Economic Affairs will set up sub-domains in order 
to draw up ten-year plans for the different areas of basic research. The 
plans will name realistic objectives for "innovations without laboratory 
animals" (NCad, 2016a, p. 3). This task is a particular challenge, as basic 
research has, until now, been regarded as sacrosanct. This makes it all 
the more important that all EU Member States actively participate in the 
drawing up of these plans. 
6 Final Remarks 
We strongly recommend transforming the current plan, Transition to Non­
Animal Research, proposed by NC ad, from an uncoordinated single process 
to a targeted joint project, in which all stakeholders stand behind the same 
goals and actively pursue them based on an overall plan. The NCad report de­
scribes crucial objectives: ending animal procedures for regulatory tests; listing 
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and prioritizing the animal-free procedures that need to be developed; and 
drawing up ten-year plans for phasing out animal procedures in the different 
areas of basic research. Under the leadership of politics, the principles that 
underlie the NCad report should be implemented in the EU Member States, 
supported by the EC, and ideally in step with international regulatory authori­
ties and scientific bodies. The implementation should be ensured by national 
and international project management, accompanied by a monitoring system, 
and made transparent to the public. A joint pursuit of the Dutch concept by 
the other EU Member States would work towards achieving the goal of Recital 
10 of Directive 2010/63/EU to replace animals for scientific and educational 
purposes. This requires a common will and joint preparation of individual 
plans in European ( or even international) workshops with all major stake­
holders, in particular science, industry, and public authorities. The successful 
phase out of animal testing in the field of cosmetics, which is gradually tak­
ing place worldwide, as well as current multi-organ on a chip developments 
across many countries, have shown that it is possible to achieve these goals 
together. 
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